Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tetrahydrofolate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOST | Q9BQB4 | 1/20 | 0.87 |
| ▸ | FPGS | Q05932 | 2/20 | 0.85 |
| ▸ | GART | P22102 | 5/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | DHFR | P00374 | 1/20 | 0.58 |
| ▸ | ATIC | P31939 | 2/20 | 0.57 |
| ▸ | MTHFD1 | P11586 | 2/20 | 0.55 |
| ▸ | MTHFD2 | P13995 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrofolate SCHEMBL31346753 | 0.98 | SOST (0.87) | SOSTFPGSGARTLMNADHFR | |
| Tetrahydrofolate SCHEMBL21248602 | 0.98 | SOST (0.87) | SOSTFPGSGARTLMNADHFR | |
| Tetrahydrofolate SCHEMBL27678337 | 0.98 | SOST (0.87) | SOSTFPGSGARTLMNADHFR | |
| Tetrahydrofolate SCHEMBL31346752 | 0.98 | SOST (0.87) | SOSTFPGSGARTLMNADHFR | |
| Tetrahydrofolate SCHEMBL31171826 | 0.97 | SOST (0.82) | SOSTFPGSGARTLMNADHFR | |
| Tetrahydrofolate SCHEMBL29067339 | 0.97 | SOST (0.84) | SOSTFPGSGARTLMNADHFR | |
| Tetrahydrofolate SCHEMBL4409552 | 0.96 | SOST (0.83) | SOSTFPGSGARTLMNADHFR | |
| Tetrahydrofolate SCHEMBL19376768 | 0.94 | SOST (0.77) | SOSTFPGSGARTLMNADHFR | |
| Tetrahydrofolate SCHEMBL1890563 | 0.94 | SOST (0.77) | SOSTFPGSGARTLMNADHFR | |
| Tetrahydrofolate SCHEMBL19376763 | 0.93 | SOST (0.77) | SOSTFPGSGARTLMNADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112121048-A | Quinolines for the combined treatment of esophageal cancer | 正大天晴药业集团股份有限公司 | 2020-12-25 | — | — | CN | claimed |
| CN-111773388-A | Combined application of A-nor-5 alpha androstane compound medicine and anticancer medicine | 上海奥奇医药科技有限公司 | 2020-10-16 | — | — | CN | claimed |
| WO-2020199973-A1 | COMBINED USE OF A-NOR-5α ANDROSTANE COMPOUND DRUG AND ANTICANCER DRUG | 上海奥奇医药科技有限公司 | 2020-10-08 | — | — | WO | claimed |
| CN-111635405-A | Production process of calcium tetrahydrofolate preparation | 无锡紫杉药业有限公司 | 2020-09-08 | — | — | CN | claimed |
| CN-103450202-B | Method for reacting L-5-methyltetrahydrofolic acid with organic base to form salt | NANJING RHINE PHARM TECHNOLOGY INC | 2015-07-01 | — | — | CN | claimed |
| CN-103664945-A | Preparation method of L-5-methyl tetrahydrofolate amino acid salt | NANJING RHINE PHARM TECHNOLOGY INC | 2014-03-26 | — | — | CN | claimed |
| CN-103450202-A | Method for reacting L-5-methyltetrahydrofolic acid with organic base to form salt | NANJING RHINE PHARM TECHNOLOGY INC | 2013-12-18 | — | — | CN | claimed |
| US-20240238271-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING CELL KILLING, AND USE THEREOF | SHANGHAI JUNCELL THERAPEUTICS CO., LTD. (CN) | 2024-07-18 | — | — | US | disclosed |
| EP-4252754-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING CELL KILLING, AND USE THEREOF | Shanghai Juncell Therapeutics Co., Ltd. (CN) | 2023-10-04 | — | — | EP | disclosed |
| CN-116761606-A | Pharmaceutical composition for enhancing cell killing and application thereof | 上海君赛生物科技有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-111773388-B | Combined application of A-nor-5 alpha androstane compound medicine and anticancer medicine | 上海奥奇医药科技有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-115414384-A | Prevention of pulmonary recurrence of cancer with cisplatin lipid complexes | 埃莱森制药有限责任公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-110357886-B | Methotrexate hapten and complete antigen as well as preparation method and application thereof | 浙江准策生物技术有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-103393688-B | Pharmaceutical composition containing calcium folinate and fluorouracil | HAINAN LINGKANG PHARMACEUTICAL | 2015-03-11 | — | — | CN | disclosed |
| CN-103664945-A | Preparation method of L-5-methyl tetrahydrofolate amino acid salt | NANJING RHINE PHARM TECHNOLOGY INC | 2014-03-26 | — | — | CN | disclosed |
| CN-103664945-A | Preparation method of L-5-methyl tetrahydrofolate amino acid salt | NANJING RHINE PHARM TECHNOLOGY INC | 2014-03-26 | — | — | CN | disclosed |
| CN-103450202-A | Method for reacting L-5-methyltetrahydrofolic acid with organic base to form salt | NANJING RHINE PHARM TECHNOLOGY INC | 2013-12-18 | — | — | CN | disclosed |
| CN-103393688-A | Pharmaceutical composition containing calcium folinate and fluorouracil | HAINAN LINGKANG PHARMACEUTICAL | 2013-11-20 | — | — | CN | disclosed |
| JP-2000136135-A | COMPOSITION USING OPTICALLY ACTIVE COMPOUND | UNIV STRATHCLYDE | 2000-05-16 | — | — | JP | disclosed |
| EP-0539987-A2 | Process for the purification of crude alkalinic earth metal salts of N(5)-methyl-5,6,7,8-tetrahydrofolic acid | Cerbios-Pharma S.A. (CH) | 1993-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238271-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING CELL KILLING, AND USE THEREOF | CTSA, GZMB, PRF1 | SOST 4477/4885FPGS 1579/4885GART 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.